Tirzepatide

Scientific identity:Tirzepatide is a 39-amino-acid synthetic peptide constructed on the native GIP(1–39) backbone with modifications that enable dual GIPR/GLP-1R agonism. Key structural features include: an Aib² substitution (α-aminoisobutyric acid at position 2) that confers DPP-IV resistance; selective amino acid substitutions at multiple positions that enable GLP-1R engagement alongside the native GIPR activity of the GIP scaffold; and a C₁₈ fatty diacid chain conjugated via a gamma-glutamic acid and mini-PEG linker to a modified lysine residue at position 20, enabling albumin binding and extended circulating half-life in experimental systems. The fatty acid conjugation strategy is conceptually related to that used in semaglutide but differs in chain length and linker composition.

Peptide class: Synthetic dual incretin receptor agonist; GIP analogue; fatty acid-conjugated modified peptide; GIPR/GLP-1R co-agonist.

Primary research targets: GIPR (glucose-dependent insulinotropic polypeptide receptor) and GLP-1R (glucagon-like peptide-1 receptor) — both class B GPCRs coupled to Gαs-mediated cAMP signaling, expressed in pancreatic beta cells, the central nervous system, adipose tissue, and other metabolically relevant tissues.

Research areas: Incretin receptor pharmacology, GIPR and GLP-1R signaling research, glucose-dependent insulin secretion models, pancreatic beta cell biology, metabolic signaling research, fatty acid-conjugated peptide pharmacology, GIP/GLP-1 axis biology.

Available quantities: 10mg, 20mg, 30mg, 60mg per vial.

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification. For laboratory research use only. Not for human or veterinary use, clinical diagnostics, compounding, or any in-vivo application in humans.

Incretin Receptor Biology

The incretin system comprises two primary hormones — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) — that are released from intestinal enteroendocrine cells in response to nutrient ingestion and act on their respective receptors in the pancreas and other tissues to potentiate glucose-dependent insulin secretion. Both GIPR and GLP-1R are class B GPCRs coupled to Gαs, elevating intracellular cAMP and activating PKA-dependent pathways in pancreatic beta cells. Research has characterised individual and combined receptor pharmacology extensively in cell-based and animal systems; tirzepatide is studied as a tool compound for examining the consequences of simultaneous GIPR and GLP-1R co-activation.

Dual Receptor Agonism Research

Published receptor pharmacology characterises tirzepatide as a biased GIPR agonist — with higher intrinsic efficacy at GIPR than GLP-1R in certain assay systems — that nonetheless produces robust GLP-1R activation. Cell-based studies have measured cAMP accumulation, insulin secretion, and receptor internalisation at both GIPR and GLP-1R in defined pancreatic and non-pancreatic cell models. The relative contribution of GIPR versus GLP-1R engagement to observed experimental effects is a subject of active research, and findings vary by cell system, receptor expression level, and measured endpoint.

Metabolic Research in Animal Models

Preclinical research in diet-induced obese and diabetic rodent models has examined tirzepatide administration in relation to glucose homeostasis parameters, insulin secretion dynamics, body weight trajectories, and tissue-level metabolic endpoints. These animal findings established the preclinical rationale that informed clinical development. They are model-specific observations that cannot be directly extrapolated to human outcomes and do not establish equivalence with the Longevia Research research vial.

Human Clinical Research and Regulatory Status

Tirzepatide has an extensive human clinical research record through the SURPASS (type 2 diabetes) and SURMOUNT (obesity) clinical trial programmes conducted by Eli Lilly. These regulated trials led to FDA approval of Mounjaro (2022) for type 2 diabetes and Zepbound (2023) for chronic weight management in adults. Additional trials have investigated tirzepatide in heart failure with preserved ejection fraction, obstructive sleep apnea, and other metabolic conditions. All human clinical findings concern pharmaceutical-grade tirzepatide under regulated conditions and do not establish the safety, efficacy, pharmacokinetic equivalence, or bioavailability of the Longevia Research research vial.

Research Status

Tirzepatide is an approved pharmaceutical compound in multiple jurisdictions. As a research tool, synthetic tirzepatide is used in incretin receptor pharmacology, GIPR/GLP-1R signalling studies, and metabolic biology research. The Longevia Research vial is supplied strictly for Research Use Only with no pharmaceutical designation, no compounding authorization, and no clinical approval in this formulation.

Reliable research begins with accurately characterised material. For a 39-amino-acid fatty acid-conjugated peptide such as tirzepatide, that means confirming sequence integrity, fatty acid conjugation, linker structure, and purity at the batch level — because an unconjugated or partially modified form produces a structurally distinct compound with a substantially different receptor binding and pharmacokinetic profile that can confound incretin receptor assays and signaling experiments.

Purity assessment: Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation: Peptide identity, fatty acid conjugation, and linker integrity are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the fully conjugated form. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis: Every vial of Tirzepatide — across all four quantity variants — is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade fatty acid-conjugated synthetic peptides.

Longevia Research supplies Tirzepatide — in 10mg, 20mg, 30mg, and 60mg vials — for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

Tirzepatide is a synthetic research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. While tirzepatide is the active pharmaceutical ingredient in FDA-approved drug products (Mounjaro and Zepbound, Eli Lilly), those approvals apply exclusively to regulated pharmaceutical formulations manufactured, tested, and distributed under pharmaceutical regulatory frameworks. No such approval applies to the Longevia Research research vial, which is not a pharmaceutical product, is not manufactured under pharmaceutical quality systems, and has not been evaluated by any regulatory authority for safety or efficacy in humans in this formulation.

This product is not supplied for compounding, reformulation, or preparation for human administration. Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific and clinical literature summarised on this product page describes observations from defined preclinical and regulated clinical research systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application from this product.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations — including regulations specific to the handling of pharmaceutical active ingredients as research compounds. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.